omeprazole has been researched along with allopurinol in 25 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (12.00) | 18.2507 |
2000's | 13 (52.00) | 29.6817 |
2010's | 8 (32.00) | 24.3611 |
2020's | 1 (4.00) | 2.80 |
Authors | Studies |
---|---|
Topliss, JG; Yoshida, F | 1 |
Gao, F; Lombardo, F; Shalaeva, MY; Tupper, KA | 1 |
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 2 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
Andersson, T; Bergstrand, R; Cederberg, C; Eriksson, S; Lagerström, PO; Skånberg, I | 1 |
Goto, H; Hamajima, E; Hoshino, H; Ozawa, T; Sugiyama, S; Tsukamoto, Y | 1 |
Bliesath, H; Hartmann, M; Koch, H; Mascher, H; Steinijans, VW; Wurst, W; Zech, K | 1 |
Bertino, JS; Bleakley, JF; Gaedigk, A; Gotschall, R; Kearns, GL; Kim, JS; Leeder, JS; Nafziger, AN; Streetman, DS | 1 |
Bertino, JS; Chainuvati, S; Gaedigk, A; Kashuba, AD; Kearns, GL; Leeder, JS; Nafziger, AN; Rowland, E; Sellers, E; Zhang, Y | 1 |
Aritürk, E; Aydin, BK; Aydin, O; Bernay, F; Biçakçi, U; Eren, Z; Rizalar, R; Tander, B | 1 |
Bertino, JS; Gaedigk, A; Kashuba, AD; Kearns, G; Leeder, JS; Nafziger, AN; Rowland, E; Sellers, E; Shelepova, T; Victory, J; Zhang, Y | 1 |
Ariturk, E; Aydin, O; Bernay, F; Bicakci, U; Cadir, FO; Kilicoglu-Aydin, B; Rizalar, R; Tander, B | 1 |
Castro, MM; Conde, SO; Nogueira, RC; Oliveira-Paula, GH; Parente, JM; Pinheiro, LC; Sanches-Lopes, JM; Tanus-Santos, JE | 1 |
1 review(s) available for omeprazole and allopurinol
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
4 trial(s) available for omeprazole and allopurinol
Article | Year |
---|---|
Omeprazole treatment does not affect the metabolism of caffeine.
Topics: Adult; Arylamine N-Acetyltransferase; Caffeine; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP1A2; Cytochrome P-450 Enzyme System; Double-Blind Method; Enzyme Induction; Humans; Male; Omeprazole; Oxidoreductases; Xanthine Oxidase | 1991 |
Pantoprazole lacks induction of CYP1A2 activity in man.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Area Under Curve; Benzimidazoles; Caffeine; Central Nervous System Stimulants; Cross-Over Studies; Cytochrome P-450 CYP1A2; Double-Blind Method; Drug Interactions; Enzyme Inhibitors; Humans; Male; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides; Xanthine Oxidase | 1999 |
Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail".
Topics: Acetyltransferases; Adult; Aryl Hydrocarbon Hydroxylases; Biomarkers; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Combinations; Genotype; Humans; Midazolam; Middle Aged; Mixed Function Oxygenases; Omeprazole; Oxidoreductases, N-Demethylating; Phenotype; Phosphodiesterase Inhibitors; Reproducibility of Results; Vitamins; Warfarin; Xanthine Oxidase | 2003 |
Effect of a triphasic oral contraceptive on drug-metabolizing enzyme activity as measured by the validated Cooperstown 5+1 cocktail.
Topics: Adult; Arylamine N-Acetyltransferase; Caffeine; Contraceptives, Oral; Cross-Over Studies; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Combinations; Drug Interactions; Ethinyl Estradiol; Female; Genotype; Humans; Midazolam; Norgestrel; Omeprazole; Therapeutic Equivalency; Vitamin K; Warfarin; Xanthine Oxidase | 2005 |
20 other study(ies) available for omeprazole and allopurinol
Article | Year |
---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
Topics: 1-Octanol; Chromatography, High Pressure Liquid; Pharmaceutical Preparations; Solubility; Water | 2001 |
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
Topics: Blood Proteins; Chemical Phenomena; Chemistry, Physical; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding | 2002 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
Effects of FK506, an immunosuppressive agent, on genesis of water-immersion stress-induced gastric lesions in rats.
Topics: Animals; Famotidine; Gastric Mucosa; Immersion; Leukotrienes; Male; Omeprazole; Peroxidase; Polyethylene Glycols; Prostaglandins; Rats; Rats, Wistar; Stomach Ulcer; Stress, Physiological; Superoxide Dismutase; Tacrolimus; Xanthine Oxidase | 1994 |
Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
Topics: Administration, Oral; Adult; Anti-Anxiety Agents; Anti-Ulcer Agents; Antitussive Agents; Aryl Hydrocarbon Hydroxylases; Arylamine N-Acetyltransferase; Caffeine; Central Nervous System Stimulants; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Combinations; Drug Interactions; Female; Genotype; Humans; Hypnotics and Sedatives; Male; Midazolam; Middle Aged; Mixed Function Oxygenases; Omeprazole; Oxidoreductases, N-Demethylating; Phenotype; Polymerase Chain Reaction; Xanthine Oxidase | 2000 |
Effects of omeprazole and gentamicin on the biochemical and histopathological alterations of the hypoxia/ reoxygenation induced intestinal injury in newborn rats.
Topics: Animals; Animals, Newborn; Anti-Bacterial Agents; Anti-Ulcer Agents; Disease Models, Animal; Enterocolitis, Necrotizing; Free Radicals; Gentamicins; Hypoxia; Intestinal Mucosa; Intestines; Malondialdehyde; Omeprazole; Rats; Rats, Wistar; Xanthine Dehydrogenase; Xanthine Oxidase | 2005 |
Protective effects of vitamin E and omeprazole on the hypoxia/reoxygenation induced intestinal injury in newborn rats.
Topics: Administration, Oral; Animals; Animals, Newborn; Anti-Ulcer Agents; Antioxidants; Disease Models, Animal; Drug Therapy, Combination; Enterocolitis, Necrotizing; Hypoxia; Injections, Intramuscular; Intestine, Small; Malondialdehyde; Omeprazole; Rats; Rats, Wistar; Spectrophotometry; Vitamin E; Xanthine Dehydrogenase; Xanthine Oxidase | 2008 |
Omeprazole induces vascular remodeling by mechanisms involving xanthine oxidoreductase and matrix metalloproteinase activation.
Topics: Allopurinol; Animals; Anti-Ulcer Agents; Aorta; Enzyme Inhibitors; Gene Expression Regulation, Enzymologic; Hydrogen-Ion Concentration; Male; Matrix Metalloproteinases; Omeprazole; Random Allocation; Rats; Rats, Wistar; Reactive Oxygen Species; Vascular Remodeling; Xanthine Dehydrogenase | 2021 |